Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

× No keyword cloud information.

17 in total

Review 1. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors: Sean T Duggan; Gillian M Keating
Journal: Drugs Date: 2011-12-24 Impact factor: 9.546

2. Chemotherapy: A new standard combination for recurrent ovarian cancer?

Authors: Robert C Bast; Maurie Markman
Journal: Nat Rev Clin Oncol Date: 2010-10 Impact factor: 66.675

3. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors: Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal: Gynecol Oncol Date: 2013-11-15 Impact factor: 5.482

Review 4. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials.

Authors: Nicoletta Staropoli; Domenico Ciliberto; Cirino Botta; Lucia Fiorillo; Anna Grimaldi; Stefania Lama; Michele Caraglia; Angela Salvino; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal: Cancer Biol Ther Date: 2014-03-21 Impact factor: 4.742

9. Glycemic Index, Glycemic Load, and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cohort.

Authors: Jennifer M Mongiovi; Jo L Freudenheim; Kirsten B Moysich; Susan E McCann
Journal: J Nutr Date: 2021-06-01 Impact factor: 4.798

10. Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Authors: Ramez N Eskander; Krishnansu S Tewari
Journal: Int J Womens Health Date: 2012-08-03

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

Review 1. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

2. Chemotherapy: A new standard combination for recurrent ovarian cancer?

3. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Review 4. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials.

Review 5. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

6. Major clinical research advances in gynecologic cancer in 2010.

Review 7. Recurrent ovarian cancer: when and how to treat.

8. New developments in treatment of ovarian carcinoma: focus on trabectedin.

9. Glycemic Index, Glycemic Load, and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cohort.

10. Emerging treatment options for management of malignant ascites in patients with ovarian cancer.